Business Context and Reporting Period
Actinium Pharmaceuticals, Inc. filed this Form 8-K on June 6, 2017, reporting material definitive agreements entered into on June 6 and June 8, 2017. The company is an emerging growth company incorporated in Delaware with headquarters at 275 Madison Avenue, New York, NY.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or debt levels. It details specific contractual financial obligations related to corporate real estate:
- Lease Term: Seven years and three months.
- Annual Rent (Years 1-4): $312,660.
- Annual Rent (Years 5-7.25): $341,610.
- Security Deposit: $390,825 (required as a letter of credit).
- License Fee (Furniture/Fixtures): $7,529 per month.
Material Changes
The company entered into an Assignment and Consent Agreement with Relmada Therapeutics, Inc., transferring the lease for the company's corporate headquarters from Relmada to Actinium. Additionally, an Amended and Restated License Agreement was executed to license furniture, fixtures, equipment, and tenant improvements at the same location, replacing a prior agreement dated March 10, 2016.
Outlook, Risks, and Contingencies
Management commentary is limited to the execution of these agreements. The filing notes that the company is responsible for additional costs including insurance, taxes, utilities, and maintenance. The company retains the right to purchase the licensed furniture and fixtures at any time during the term. No specific risks or contingencies beyond the standard obligations of the lease and license were disclosed in this text.
Investor Verification Checklist
- Verify the total cash impact of the $390,825 letter of credit requirement on current liquidity.
- Confirm the exact commencement date of the lease to calculate the precise start of the rental payment schedule.
- Review the upcoming Form 10-Q for the quarter ending June 30, 2017, for the full text of the Assignment Agreement and Lease exhibits.
- Assess the valuation of the furniture and fixtures (FFE) to determine the potential cost if the purchase option is exercised.